In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters
Open Access
- 27 February 2021
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 3, 100073
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- University of Texas at Austin
This publication has 33 references indexed in Scilit:
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading ExoribonucleasemBio, 2018
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- The use of captisol (SBE7-β-CD) in oral solubility-enabling formulations: Comparison to HPβCD and the solubility–permeability interplayEuropean Journal of Pharmaceutical Sciences, 2015
- Naive Pooled–Data Approach for Pharmacokinetic Studies in Pediatrics With a Very Small Sample SizeAmerican Journal of Therapeutics, 2014
- Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to miceEuropean Journal of Pharmaceutics and Biopharmaceutics, 2012
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft ExcelComputer Methods and Programs in Biomedicine, 2010
- Formulation strategy and use of excipients in pulmonary drug deliveryInternational Journal of Pharmaceutics, 2010
- Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solutionEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Improved Aqueous Solubility of Crystalline Astaxanthin (3,3′‐dihydroxy‐β, β‐carotene‐4,4′‐dione) by Captisol® (Sulfobutyl Ether β‐Cyclodextrin)Journal of Pharmaceutical Sciences, 2003
- Sparse-Sampling Optimal Designs in Pharmacokinetics and ToxicokineticsDrug Information Journal, 1995